Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Ad26.COV2.S
Omicron
SARS-CoV-2
Variant of concern
antibody-dependent cellular cytotoxicity
breakthrough infection
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
03
01
2022
revised:
19
01
2022
accepted:
27
01
2022
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.
Identifiants
pubmed: 35474744
doi: 10.1016/j.xcrm.2022.100535
pii: S2666-3791(22)00035-0
pmc: PMC8828412
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100535Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203135/Z/16/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
P.L.M. is a member of the advisory board for Cell Reports Medicine. All other authors declare no competing interests.
Références
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
EBioMedicine. 2021 Dec;74:103748
pubmed: 34902788
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
JAMA. 2022 Jan 11;327(2):179-181
pubmed: 34914825
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Nat Rev Immunol. 2020 Dec;20(12):727-738
pubmed: 33139888
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2021 Jun 3;384(22):2161-2163
pubmed: 33826816
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2020 Dec 10;183(6):1508-1519.e12
pubmed: 33207184
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Sci Transl Med. 2022 Apr 20;14(641):eabn6150
pubmed: 35258323
Cell Rep Med. 2022 Jan 17;3(2):100510
pubmed: 35233544
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625